Enveric Biosciences (ENVB)
(Delayed Data from NSDQ)
$0.90 USD
-0.01 (-0.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.91 +0.02 (1.68%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Enveric Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 18 | 17 | 2 | 0 |
Receivables | 0 | 0 | 0 | 0 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 0 | 1 | 1 |
Total Current Assets | 4 | 18 | 18 | 2 | 8 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 9 | 2 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4 | 20 | 27 | 4 | 25 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 1 | 1 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 5 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 0 | 0 | 0 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 3 | 1 | 0 | 3 |
Total Current Liabilities | 2 | 4 | 2 | 1 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 2 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 1 | 0 | 0 | 0 |
Total Liabilities | 2 | 5 | 4 | 1 | 14 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 101 | 94 | 83 | 15 | 51 |
Retained Earnings | -97 | -79 | -61 | -12 | -41 |
Other Equity | -2 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2 | 15 | 22 | 3 | 11 |
Total Liabilities & Shareholder's Equity | 4 | 20 | 27 | 4 | 25 |
Total Common Equity | 2 | 15 | 22 | 3 | 11 |
Shares Outstanding | 2.70 | 2.00 | 0.60 | 0.20 | 0.00 |
Book Value Per Share | 0.73 | 7.34 | 37.18 | 16.95 | 10.62 |
Fiscal Year End for Enveric Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 4 | 7 | 13 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 2 | 2 | 2 |
Total Current Assets | NA | 4 | 6 | 9 | 15 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 4 | 7 | 10 | 16 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 2 | 2 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 2 | 2 | 2 |
Total Current Liabilities | NA | 2 | 4 | 5 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 1 |
Total Liabilities | NA | 2 | 4 | 5 | 5 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 101 | 96 | 96 | 95 |
Retained Earnings | NA | -97 | -93 | -90 | -84 |
Other Equity | NA | -2 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 2 | 2 | 5 | 10 |
Total Liabilities & Shareholder's Equity | NA | 4 | 7 | 10 | 16 |
Total Common Equity | 0 | 2 | 2 | 5 | 10 |
Shares Outstanding | 7.20 | 2.70 | 2.10 | 2.00 | 2.00 |
Book Value Per Share | 0.00 | 0.73 | 1.16 | 2.44 | 5.21 |